Perspective: Research highlights at the UCLA center for AIDS research. Constraints on the sequence diversity of the protease of human immunodeficiency virus type 1: A guide for drug design

AIDS Research and Human Retroviruses

Volumn 12, Issue 10, 1996, Pages 849-853

  Kaplan, Andrew H ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAG PROTEIN; POL PROTEIN; PROTEINASE; PROTEINASE INHIBITOR; STRUCTURAL PROTEIN; VIRUS ENZYME; VIRUS RNA; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT;

DRUG DESIGN; GENETIC VARIABILITY; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL RESEARCH; PRIORITY JOURNAL; REVIEW; VIRUS GENE; ACQUIRED IMMUNE DEFICIENCY SYNDROME; ENZYMOLOGY; GENETICS; HUMAN;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTI-HIV AGENTS; DRUG DESIGN; HIV PROTEASE; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; VARIATION (GENETICS);

EID: 0030187261     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/aid.1996.12.849     Document Type: Review

References (53)

1. Condra JH, Schleif W, Blahy OM, Gabryelski LJ, Graham DJ, Quintero JC, Rhodes A, Robbins HL, Roth E, Shivaprakash M, Titus D, Yang T, Tepler H, Squires KE, Deutsch PJ, and Emini EA: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature (London) 1995;374:569-571.
2. Norbeck DW and Kempf DJ: HIV-1 protease inhibitors. Annu Rep Med Chem 1991;26:141-150.
3. Tomasselli AG, Howe WJ, Sawyer TK, Wlodawer A, and Heinrikson RL: The complexities of AIDS: An assessment of the HIV protease as a therapeutic target. Chim Oggi 1991:6-27.
4. Wlodawer A and Erickson J: Structure-based inhibitors of the HIV-1 protease. Annu Rev Biochem 1993;62:543-585.
5. Markowitz M, Saag M, Powderly WG, Hurley Am, Hsu A, Valdes JM, Henry D, Sattler F, La Marca A, Leonard JM, and Ho DD: A preliminary study of ritonavir, an inhibitor of HIV-1 protease, to treat HIV-1 infection. New Engl J Med 1995;333:1534-1539.
6. Collier AC, Coombs RW, Schoenfeld DA, Basset RL, Timpone J, Baruch A, Jones M, Facey K, Whitacre C, McAuliffe VJ, Friedman HM, Merigan TC, Reichman RC, Hooper C, and Corey L: Treatment of human immunodeficiency virus infection with saquinavir, zidovudine, and zalcitabine. New Engl J Med 1995;334:1011-1017.
7. el-Farrash MA, Kuroda MJ, Kitazaki T, Masuda T, Kato K, Hatanaka M, and Harada S: Generation and characterization of a human immunodeficiency virus type 1 (HIV-1) mutant resistant to an HIV-1 protease inhibitor. J Virol 1994;68:233-239.
8. Ho DD, Toyoshima T, Mo H, Kempf DJ, Norbeck D, Chen CM, Wideburg NE, Burt SK, Erickson JW, and Singh MK: Characterization of human immunodeficiency virus type 1 variants with increased resistance to a C2-symmetric protease inhibitor. J Virol 1994;68:2016-2020.
9. Jacobsen H, Yasargil K, Winslow DL, Craig JC, Krohn A, Duncan IB, and Mous J: Characterization of human immunodeficiency virus type 1 mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology 1995;206:527-534.
10. Kaplan AH, Michael SF, Wehbie RS, Knigge MF, Paul DA, Everitt L, Kempf DJ, Norbeck DW, Erickson J, and Swanstrom R: Selection of multiple HIV-1 variants with decreased sensitivity to an inhibitor of the viral protease. Proc Natl Acad Sci USA 1994;91:5597-5601.
11. Lin Y, Lin X, Hong L, Foundling S, Heinrikson RL, Thaisrivongs S, Leelamanit W, Raterman D, Shah M, Dunn BM, and Tang J: Effect of point mutations on the kinetics and the inhibition of human immunodeficiency virus type 1 protease: Relationship to drug resistance. Biochemistry 1995;34:1143-1152.
12. Markowitz M, Mo H, Kempf DJ, Norbeck DW, Bhat TN, Erickson JW, and Ho DD: Selection and analysis of human immunodeficiency virus type 1 variants with increased resistance to ABT-538, a novel protease inhibitor. J Virol 1995;69:701-706.
13. 2 symmetrical inhibitors of HIV type 1 protease. Proc Natl Acad Sci USA 1993;90:7543-7547.
14. Partaledis JA, Yamaguchi K, Tisdale M, Blair EE, Falcione C, Maschera B, Myers RE, Pazhanisamy S, Futer O, Cullinan AB, Stuver CM, Byrne RA, and Livingston DJ: In vitro selection and characterization of human immunodeficiency virus type 1 isolates with reduced sensitivity to hydroxyethylamino sulfonamide inhibitors of HIV-1 aspartyl protease. J Virol 1995;69:5228-5235.
15. Patick AK, Rose R, Greytok J, Bechtold CM, Hermsmeier MA, Chen PT, Barris JC, Zahler R, Colonno RJ, and Lin PF: Characterization of a human immunodeficiency virus type 1 variant with reduced sensitivity to an aminodiol protease inhibitor. J Virol 1995;69:2148-2152.
16. Sardana VV, Schlabach AJ, Graham P, Bush BL, Condra JH, Culberson JC, Gotlib L, Graham DJ, Kohl NE, LaFemina RL, Schneider CL, Wolanski BS, Wolfgang JA, and Emini EA: Human immunodeficiency virus type 1 protease inhibitors: Evaluation of resistance engendered by amino acid substitutions in the enzyme's substrate binding site. Biochemistry 1994;33:2004-2010.
17. Erickson J: The not-so-great escape. Nature Struct Biol 2:523-529.
18. Turriziani O, Antonelli G, Jacobsen H, Mous J, Riva E, Pistello M, and Dianzani F: Identification of an amino acid substitution involved in the reduction of sensitivity of HIV-1 to an inhibitor of viral proteinase. Acta Virol 1994;38:297-298.
19. Ho DD, Neumann AU, Perelson AS, Chen W, Leonard JM, and Markowitz M: Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection. Nature (London) 1995;373:123-126.
20. Wei X, Ghosh SK, Taylor ME, Johnson VA, Emini EA, Deutsch P, Lifson JD, Bonhoeffer S, Nowak MA, Hahn BH, Saag MS, and Shaw GM: Viral dynamics in human immunodeficiency virus type 1 infection. Nature (London) 1995;373:117-122.
21. Coffin JM: HIV population dynamics in vivo: Implications for genetic variation, pathogenesis, and therapy. Science 1995;267: 483-489.
22. Dickson C, Eisenman R, Fan H, Hunter E, and Teich N: RNA tumor viruses. In: Molecular Biology of Tumor Viruses. (Weiss RA, Teich RA, Varmus HE, and Coffin JM, eds.). Cold Spring Harbor Press, Cold Spring Harbor, New York, 1984.
23. Oroszlan S and Luftig RB: Retroviruses: Strategies of replication. In: Current Topics in Microbiology and Immunology (Swanstrom R and Vogt PK, eds.). Springer-Verlag, Berlin, 1990.
24. Kaplan AH, Zack JA, Knigge M, Paul DA, Kempf DJ, Norbeck DW, and Swanstrom R: Partial inhibition of the human immunodeficiency virus, type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. J Virol 1993;67: 4050-4055.
25. Kohl NE, Emini EA, Schleif WA, Davis LJ, Heimbach JC, Dixon RA, Scolnick EM, and Sigal IS: Active human immunodeficiency virus protease is required for viral infectivity. Proc Natl Acad Sci USA 1988;85:4686-4690.
26. Peng C, Ho B, Chang T, and Chang N: Role of human immunodeficiency virus type 1 specific protease in core maturation and viral infectivity. J Virol 1989;63:2550-2556.
27. Loeb DD, Swanstrom R, Everitt L, Manchester M, Stamper SE, and Hutchinson CE: Complete mutagenesis of the HIV-1 protease. Nature (London) 1989;340:397-400.
28. Navia MA, Fitzgerald PM, McKeever BM, Leu CT, Heimbach JC, Herber WK, Sigal IS, Darke PL, and Springer JP: Three-dimensional structure of aspartyl protease from human immunodeficiency virus HIV-1. Nature (London) 1989;337:615-620.
29. Miller M, Jaskolski M, Rao JK, Leis J, and Wlodawer A: Crystal structure of a retroviral protease proves relationship to aspartic protease family. Nature (London) 1989;337:576-579.
30. Weber IT, Miller M, Jaskolski M, Leis J, Skalka AM, and Wlodawer A: Molecular modeling of the HIV-1 protease and its substrate binding site. Science 1989;243:928-931.
31. Reicin AS, Paik S, Berkowitz RD, Luban J, Lowy I, and Goff SP: Linker insertion mutations in the human immunodeficiency virus type 1 gag gene: Effects on virion particle assembly, release, and infectivity. J Virol 1995;69:642-650.
32. Vogt VM, Eisenman R, and Diggelmann H: Generation of AMV structural proteins by proteolytic cleavage of a precursor polypeptide. J Mol Biol 1975;96:471-493.
33. Arcement LJ, Karshin WL, Naso RB, and Arlinghous RB: "gag" polypeptide precursors of Rauscher murine leukemia virus. Virology 1977;81:284-297.
34. Lu AH, Soong MM, and Wong PKY: Maturation of Moloney murine leukemia virus. Virology 1979;93:269-274.
35. Kaplan AH, Manchester M, and Swanstrom R: The activity of the protease of human immunodeficiency virus type 1 is initiated at the membrane of infected cells before the release of viral proteins and is required for release to occur with maximum efficiency. J Virol 1994;68:6782-6786.
36. Peng C, Ho B, Chang T, and Chang N: Role of human immunodeficiency virus type 1 specific protease in core maturation and viral infectivity. J Virol 1989;63:2550-2556.
37. Lori F, Scorassi AI, Zella D, Achilli G, Cattaneo E, Casoli C, and Bertazzoni U: Enzymatically active forms of reverse transcriptase of the human immunodeficiency virus. AIDS Res Hum Retroviruses 1988;4:393-399.
38. Crawford S, and Goff SP: A deletion mutant in the 5′ part of the pol gene of Moloney murine leukemia virus blocks proteolytic processing of the gag and pol polyproteins. J Virol 1985;53:899-907.
39. Stewart L, Schatz G, and Vogt VM: Properties of avian retrovirus particles defective in viral protease. J Virol 1990;64:5076-5092.
40. Kaplan AH, Krogstad P, Kempf D, Norbeck D, and Swanstrom R: HIV-1 virions composed of unprocessed Gag and Gag/Pol precursors are capable of efficiently reverse transcribing the viral genomic RNA. Antimicrob Agents Chemother 1994;38:2929-2933.
41. Pettit SC, Simsic J, Loeb DD, Everitt L, Hutchinson CA III, and Swanstrom R: Analysis of retroviral protease cleavage sites reveals two types of cleavage sites and the structural requirements of the P1 amino acid. J Biol Chem 1991;266:14539-14547.
42. Poorman RA, Tomasselli AG, Heinrikson RL, and Kezdy FJ: A cumulative specificity model for proteases from HIV-1 and 2 inferred from statistical analysis of an extended substrate data base. J Biol Chem 1991;266:14554-14561.
43. Moore ML, Bryan WM, Fakhoury SA, Magaard VW, Huffman WF, Dayton DB, Meek T, Hyland L, Dreyer GB, and Metcalf BW: Peptide substrates and inhibitors of the HIV-1 protease. Biochem Biophys Res Commun 1989;159:420-425.
44. Jaskolski M, Tomasselli AG, Sawyer TK, Staples DG, Heinrikson RL, Schneider J, Kent SB, and Wlodawer A: Structure at 2.5-Å resolution of chemically synthesized HIV-1 protease complexed with a hydroxyethylene-based inhibitor. Biochemistry 1991;30: 1600-1609.
45. Miller M, Schneider J, Sathyanarayana BK, Toth MV, Marshall GR, Clawson L, Selk L, Kent SB, and Wlodawer A: Structure of complex of synthetic HTV-1 protease with a substrate-based inhibitor at 2.3-Å resolution. Science 1989;246:1149-1152.
46. Swain AL, Miller MM, Green J, Rich DH, Schneider J, Kent SB, and Wlodawer A: X-Ray crystallographic structure of a complex between a synthetic protease of HIV-1 and a substrate-based hydroxyethylamine inhibitor. Proc Natl Acad Sci USA 1990; 87:8805-8809.
47. Dreyer GB, Lambert DM, Meek TD, Carr TJ, Tomaszek TA, Bartus H, Cacciavillani E, Hasell AM, and Minnich M: Hydroxyethylene isostere inhibitors of HIV-1 protease: Structure-activity analysis using enzyme kinetics, X-ray crystallography, and infected T-cell assays. Biochemistry 1992;31:6646-6659.
48. 2 symmetric inhibitor complexed to HIV-1 protease. Science 1990;249:527-533.
49. Thompson WJ, Fitzgerald PM, Holloway MK, Emini EA, Darke PL, McKeever BM, Schlief WA, Quintero JC, Zugay JA, and Tucker TJ: Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionally tethered P1 or P1′ phenyl substituents: X-ray crystal structure assisted design. J Med Chem 1992;35:1685-1701.
50. 2 symmetric inhibitors of HIV protease. J Med Chem 1990;33:2687-2689.
51. 2 symmetric inhibitors of the HIV-1 protease. Antimicrob Agents Chemother 1991;35:2209-2214.
52. Lech WJ, Wang G, Yang YL, Chee Y, Dorman K, McCrae D, Lazzeroni LC, Erickson JW, Sinsheimer JS, and Kaplan AH: In vivo sequence diversity of the protease of the human immunodeficiency virus type I: Presence of protease inhibitor resistant variants in untreated subjects. J Virol 1996;70:2038-2043.
53. Rose RE, Gong Y-F, Greytok JA, Bechtold CM, Terry BJ, Robinson BS, Alam M, Colonno RJ, and Lin P-F: Human immunodeficiency virus type 1 background plays a major role in development of resistance to protease inhibitors. Proc Natl Acad Sci 1996;93:1648-1653.